Trastuzumab Deruxtecan with Bevacizumab for HER2-Expressing Ovarian Cancer
Tests trastuzumab deruxtecan with bevacizumab in adults with HER2-expressing advanced ovarian cancer.
Plain-language title generated from the registry record
Registry title: Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Key facts
- Where
- Bucharest and Oradea, RomaniaSee the 4 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?
- Which best describes your most recent course of platinum chemotherapy (such as carboplatin or cisplatin)?
- Have your doctors told you that your cancer is advanced (stage 3 or 4)? This means it has spread beyond the ovaries to other parts of the belly or the body, even if it was later removed by surgery.
- What type of ovarian cancer do you have?
Source: NCT06819007, who can take part
Where in Romania
- Gral Medical S.R.LBucharest, RomaniaTaking people
- Medeuropa S.R.L.Bucharest, RomaniaTaking people
- Memorial Healthcare International S R LBucharest, RomaniaTaking people
- Medeuropa S.R.L.Oradea, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT06819007EU 2024-516982-35-00
- Record updated
- 28 October 2026
- Original description
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.Read full original descriptionShow less
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Inclusion: Sign and date the tissue prescreening informed consent form (ICF), prior to HER2 central testing. Sign and date the Main ICF prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures; *For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualification procedures; Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old; Has histologically confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma per local assessment (including but not limiting to serous, endometrioid, clear cell, carcinosarcoma, mucinous); Is newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV; Has HER2 expression.
Exclusion: Has a known or suspected deleterious BRCA alteration as per local test that makes the participant eligible for poly (ADP-ribose) polymerase (PARP) inhibitor; Participant to receive PARP inhibitor as maintenance per standard of care and investigator discretion; Previous cerebral-vascular accident, transient ischemic attack or subarachnoid hemorrhage within 6 months prior to randomization; *Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable; Has ovarian, fallopian tube, or peritoneal cancer of non-epithelial origin; Has evidence of bleeding diathesis or significant coagulopathy (in the absence of anticoagulation therapy); Has a history of hemorrhagic disorders.